Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab With or Without Bevacizumab in Unresectable Stage III or Stage IV Melanoma
NCT01950390Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2014
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in melanoma, sponsored by National Cancer Institute. Started Jan 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01950390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01950390.